Atara biotherapeutics announces first quarter 2023 financial results and operational progress

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “we are entering an important period of potential value-generating milestones for our prioritized pipeline.
ATRA Ratings Summary
ATRA Quant Ranking